Germany Could Introduce Biosimilar Substitution By Pharmacists In Three Years

A German bill aims to cut spending on biologics, but new revisions mean that measures on biosimilar substitution are likely to be delayed by three years.

GermanFlag
Germany Plans To Introduce Biosimilar Substitution • Source: Shutterstock

Pharmacists in Germany could be permitted to switch biologics with biosimilars if a new bill makes it through the legislative process. Though recent revisions to the bill could delay this measure by three years, once in force, it would likely have a substantial impact on the pharmaceutical industry. Manufacturers of originator biologics could be exposed to lower sales and increased pricing pressure, according to Eda Zhuleku, a life science specialist at the law firm Allen & Overy.

On Jan. 30, the German cabinet approved a revised text of the bill (GSAV, Act for Greater Security in the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography